Incyte bolsters haematology portfolio in $2bn Vega buyout - Pharmaceutical Technology

This acquisition will see Incyte absorb Vega's bleeding disorder candidate, VG039, which is in Phase III for von Willebrand disease (VWD). The Vega acquisition will see Incyte absorb its first-in-class bleeding disorder candidate, VG039. Incyte will absorb VGA039, Vega’s late-stage candidate for bleeding disorder, von Willebrand disease, through this acquisition. Credit: eamesBot / Shutterstock.com. Incyte has outlaid up to $2bn to acquire Star Therapeutics-owned subsidiary, Vega Therapeutics – adding a late-stage candidate to its haematology portfolio. For an upfront sum of $1.25bn, with additional payments of up to $750m depending on the achievement of sales milestones, Incyte will secure the…

Source: Pharmaceutical Technology